• Science
  • Authentic expertise and the Science of substance management

Genome BC Invests in ALAViDA

  • Science
  • Article


Genome BC Invests in ALAViDA


Vancouver, Canada — Heavy drinking is associated with the risk of developing health problems such as mental and behavioural disorders, including alcohol dependence, major noncommunicable diseases such as liver cirrhosis, some cancers and cardiovascular diseases. It is also associated with injuries resulting from violence and road collisions.

Many believe 12-step intervention programs, such as Alcoholics Anonymous are the only way to overcome addiction. While this traditional treatment approach may be effective for some, it may not work for everyone. Decades of mounting scientific evidence show therapeutic and pharmaceutical interventions can be also effective.

To broaden support and accessibility for treating addictions, Genome BC has invested in BC based ALAViDA Health Ltd.— a Vancouver based digital health company that offers a new approach to treatment and an alternative to 12-step programs.

Read more here. Also featured on Markets Insider and Newswire.

Genome British Columbia  leads genomics innovation on Canada’s West Coast and facilitates the integration of genomics into society. A recognized catalyst for government and industry, Genome BC invests in research, entrepreneurship and commercialization in life sciences to address challenges in key sectors such as health, forestry, fisheries and aquaculture, agrifood, energy, mining and environment. Genome BC partners with many national and international public and private funding organizations to drive BC’s bioeconomy. genomebc.ca

Access the ALAViDA TRAiL app.